Cyclacel Pharmaceuticals (CYCC) Getting Favorable Press Coverage, Study Shows
Media coverage about Cyclacel Pharmaceuticals (NASDAQ:CYCC) has trended positive recently, Accern Sentiment reports. Accern identifies positive and negative media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cyclacel Pharmaceuticals earned a news sentiment score of 0.25 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 46.0787109068099 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the news headlines that may have impacted Accern’s scoring:
- Cyclacel Pharmaceuticals Inc : Investor Network: Cyclacel Pharmaceuticals, Inc. to Host Earnings Call (4-traders.com)
- Cyclacel Pharmaceuticals Reports Second Quarter 2017 Financial Results – GlobeNewswire (press release) (globenewswire.com)
- Shares Trading Near the 52-Week Low Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) – Sparta Review (spartareview.com)
- Cyclacel Pharmaceuticals, Inc. (CYCC) noted a price change of 4.73 … – Stocks Gallery (stocksgallery.com)
- Cyclacel Pharmaceuticals, Inc. (CYCC)- Safe Haven Performance Portfolio Stocks – NASDAQ Times (nasdaqtimes.com)
Cyclacel Pharmaceuticals (NASDAQ:CYCC) opened at 1.69 on Thursday. Cyclacel Pharmaceuticals has a 1-year low of $1.56 and a 1-year high of $10.90. The stock has a 50 day moving average of $2.85 and a 200 day moving average of $4.29.
Cyclacel Pharmaceuticals (NASDAQ:CYCC) last issued its quarterly earnings results on Thursday, May 11th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter. Cyclacel Pharmaceuticals had a negative return on equity of 72.48% and a negative net margin of 1,128.13%. Equities analysts expect that Cyclacel Pharmaceuticals will post ($2.25) earnings per share for the current fiscal year.
Separately, Zacks Investment Research downgraded shares of Cyclacel Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, April 26th.
In related news, major shareholder Eastern Capital Ltd purchased 850,000 shares of the stock in a transaction that occurred on Wednesday, July 19th. The stock was bought at an average cost of $2.00 per share, for a total transaction of $1,700,000.00. Following the completion of the transaction, the insider now directly owns 2,167,261 shares in the company, valued at $4,334,522. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 4.00% of the stock is owned by company insiders.
About Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors.
Receive News & Stock Ratings for Cyclacel Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.